Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Change in Inventory (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Change in Inventory for 16 consecutive years, with $1.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Inventory rose 174.4% to $1.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$30000.0, a 100.32% decrease, with the full-year FY2025 number at -$30000.0, down 100.32% from a year prior.
  • Change in Inventory was $1.8 million for Q4 2025 at Anika Therapeutics, up from $443000.0 in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $4.7 million in Q2 2024 to a low of -$2.4 million in Q4 2024.
  • A 5-year average of $1.7 million and a median of $2.2 million in 2022 define the central range for Change in Inventory.
  • Peak YoY movement for Change in Inventory: skyrocketed 690.36% in 2022, then plummeted 176.17% in 2024.
  • Anika Therapeutics' Change in Inventory stood at -$498000.0 in 2021, then surged by 690.36% to $2.9 million in 2022, then grew by 6.77% to $3.1 million in 2023, then tumbled by 176.17% to -$2.4 million in 2024, then soared by 174.4% to $1.8 million in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Change in Inventory are $1.8 million (Q4 2025), $443000.0 (Q3 2025), and -$1.7 million (Q2 2025).